Thomasville National Bank Acquires 3,183 Shares of Zoetis Inc. $ZTS

Key Points

• Thomasville National Bank increased its stake in Zoetis Inc. by 3.8%, acquiring an additional 3,183 shares during the second quarter, bringing their total holdings to 87,472 shares valued at approximately $13.6 million.
• Analyst ratings for Zoetis have been mixed, with some firms downgrading their ratings while others, like Piper Sandler, raised their target price from $210 to $215, reflecting a consensus rating of "Moderate Buy" with a target price of $200.88.
• Zoetis reported better-than-expected earnings with an EPS of $1.76 for the last quarter, surpassing estimates and reflecting a 4.2% year-over-year revenue increase, resulting in revenue of $2.46 billion.

Thomasville National Bank increased its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 3.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 87,472 shares of the company's stock after acquiring an additional 3,183 shares during the quarter. Thomasville National Bank's holdings in Zoetis were worth $13,641,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the company. Brighton Jones LLC lifted its stake in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock worth $754,000 after purchasing an additional 2,978 shares during the period. Two Sigma Advisers LP grew its holdings in Zoetis by 18.4% during the 4th quarter. Two Sigma Advisers LP now owns 39,900 shares of the company's stock worth $6,501,000 after acquiring an additional 6,200 shares during the last quarter. Waverly Advisors LLC acquired a new stake in Zoetis in the 4th quarter valued at about $494,000. Focus Partners Advisor Solutions LLC increased its position in Zoetis by 39.0% in the 4th quarter. Focus Partners Advisor Solutions LLC now owns 2,736 shares of the company's stock valued at $446,000 after acquiring an additional 768 shares in the last quarter. Finally, Vise Technologies Inc. lifted its position in shares of Zoetis by 64.1% during the fourth quarter. Vise Technologies Inc. now owns 5,602 shares of the company's stock worth $913,000 after purchasing an additional 2,189 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Trading Down 0.9%

ZTS traded down $1.28 during trading on Friday, reaching $145.82. 4,455,824 shares of the company's stock were exchanged, compared to its average volume of 2,273,605. The company's fifty day moving average price is $151.25 and its 200-day moving average price is $156.52. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $197.51. The firm has a market capitalization of $64.63 billion, a PE ratio of 25.10, a P/E/G ratio of 2.34 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the prior year, the business posted $1.56 EPS. The firm's quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Analysts Set New Price Targets

ZTS has been the topic of several research analyst reports. Argus reissued a "buy" rating and set a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Piper Sandler boosted their target price on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and cut their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.